Dawn Holcombe on Muck Rack

Dawn Holcombe

Verified
South Windsor
As seen in: Oncology Practice Management, NewsBreak, American Journal of Managed Care, The Connecticut Mirror, Journal of Oncology Navigation and Survivorship, Value-Based Cancer Care, The Oncology Pharmacist, Value-Based Care in Rheumatology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dawn

Contact Dawn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Needy CT patients won’t benefit from 340B changes

|
By Dawn Holcombe Verified
| The Connecticut Mirror Verified
Recently, the Human Services Committee of the Connecticut General Assembly reported a bill out of the committee with proposed changes to the 340B Drug Pricing Program. The legislation as amended, SB 494, includes a provision that would require biopharmaceutical manufacturers to ship 340B drugs to all contract pharmacies that contract with 340B “covered entities,” and by extension offer 340B pricing at these locations.
Open in Who Shared Issue with article?

March 2026, Vol 16, No 2

|
By Meg Barbor, Shawntea Gordon, Dawn Holcombe Verified
| Oncology Practice Management Verified
On February 10, 2026, the FDA approved pembrolizumab (Keytruda) and pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with paclitaxel, with or without bevacizumab, for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumors express PD-L1 (CPS≥1) and who have received 1 or 2 prior systemic treatments. Read More ›
Open in Who Shared Issue with article?

Major PBM Reform in Play? Shell Games Require Action

|
By Dawn Holcombe Verified
| Oncology Practice Management Verified
January and February have brought significant activity on the pharmacy benefit reform front at the federal level—a long time in coming, but it is not yet time to celebrate. Separate federal and congressional focus on pharmacy benefits management (PBM) oversight initiatives have the potential to create significant changes as they compound on future and past efforts to better manage health benefit coverage.
Open in Who Shared Issue with article?
See all 60 licensed articles (61 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified